JP2010536372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536372A5 JP2010536372A5 JP2010521887A JP2010521887A JP2010536372A5 JP 2010536372 A5 JP2010536372 A5 JP 2010536372A5 JP 2010521887 A JP2010521887 A JP 2010521887A JP 2010521887 A JP2010521887 A JP 2010521887A JP 2010536372 A5 JP2010536372 A5 JP 2010536372A5
- Authority
- JP
- Japan
- Prior art keywords
- mirna
- urine
- specific
- sample
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002679 microRNA Substances 0.000 claims description 147
- 210000002700 urine Anatomy 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 117
- 239000000523 sample Substances 0.000 claims description 67
- 230000030833 cell death Effects 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 210000001124 body fluid Anatomy 0.000 claims description 39
- 239000010839 body fluid Substances 0.000 claims description 39
- 210000000056 organ Anatomy 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 18
- 238000009396 hybridization Methods 0.000 claims description 16
- 238000012544 monitoring process Methods 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 15
- 108091070501 miRNA Proteins 0.000 claims description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims description 14
- 208000018737 Parkinson disease Diseases 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 11
- 201000010374 Down Syndrome Diseases 0.000 claims description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 9
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 230000001605 fetal effect Effects 0.000 claims description 8
- 230000001351 cycling effect Effects 0.000 claims description 7
- 238000007834 ligase chain reaction Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000035935 pregnancy Effects 0.000 claims description 5
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229960004198 guanidine Drugs 0.000 claims description 4
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 claims description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 4
- 108700004121 sarkosyl Proteins 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 230000008520 organization Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 description 152
- 210000001519 tissue Anatomy 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 34
- 208000006011 Stroke Diseases 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000034994 death Effects 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 230000002485 urinary effect Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 8
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000005349 anion exchange Methods 0.000 description 8
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 8
- 230000016273 neuron death Effects 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 241000894007 species Species 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000012614 Q-Sepharose Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 4
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000036830 Normal foetus Diseases 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102100023961 ADP-ribosylation factor-like protein 2-binding protein Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- -1 ELISA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000022471 Fetal disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018478 Foetal disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000757692 Homo sapiens ADP-ribosylation factor-like protein 2-binding protein Proteins 0.000 description 1
- 108091069086 Homo sapiens miR-127 stem-loop Proteins 0.000 description 1
- 108091068985 Homo sapiens miR-137 stem-loop Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000009789 autophagic cell death Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 231100000859 kill neurons Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012284 sample analysis method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96587107P | 2007-08-22 | 2007-08-22 | |
| US60/965,871 | 2007-08-22 | ||
| PCT/US2008/009991 WO2009025852A2 (en) | 2007-08-22 | 2008-08-22 | Methods of using mirna for detection of in vivo cell death |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536372A JP2010536372A (ja) | 2010-12-02 |
| JP2010536372A5 true JP2010536372A5 (https=) | 2011-10-06 |
| JP5416110B2 JP5416110B2 (ja) | 2014-02-12 |
Family
ID=40378881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521887A Expired - Fee Related JP5416110B2 (ja) | 2007-08-22 | 2008-08-22 | ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8486626B2 (https=) |
| EP (2) | EP2195450B2 (https=) |
| JP (1) | JP5416110B2 (https=) |
| CN (2) | CN105400868B (https=) |
| AU (2) | AU2008289447B2 (https=) |
| CA (1) | CA2696403C (https=) |
| CY (1) | CY1114111T1 (https=) |
| DK (2) | DK2612926T3 (https=) |
| ES (2) | ES2660785T3 (https=) |
| HR (1) | HRP20130618T1 (https=) |
| HU (1) | HUE019019T5 (https=) |
| NO (1) | NO2612926T3 (https=) |
| PL (2) | PL2612926T3 (https=) |
| PT (2) | PT2612926T (https=) |
| TR (1) | TR201802758T4 (https=) |
| WO (1) | WO2009025852A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009132273A2 (en) * | 2008-04-25 | 2009-10-29 | Merck & Co., Inc. | Microrna biomarkers of tissue injury |
| WO2010004562A2 (en) * | 2008-07-09 | 2010-01-14 | Rosetta Genomics Ltd. | Methods and compositions for detecting colorectal cancer |
| EP2853601B1 (en) * | 2008-07-18 | 2016-09-21 | TrovaGene, Inc. | Methods for PCR-based detection of "ultra short" nucleic acid sequences |
| EP2419536A4 (en) * | 2009-04-14 | 2012-09-05 | Merck Sharp & Dohme | MICRO RNA AS A BIOMARKER FOR IMPROVING BETAZELLES IN THE PANCREAS ISLANDS |
| WO2011006119A2 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| US8648017B2 (en) * | 2009-11-04 | 2014-02-11 | Diamir, Llc | Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
| JP2013509883A (ja) | 2009-11-06 | 2013-03-21 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 臓器移植患者における移植片拒絶反応の非侵襲的診断方法 |
| WO2011143659A2 (en) * | 2010-05-14 | 2011-11-17 | Fluidigm Corporation | Nucleic acid isolation methods |
| RU2626540C2 (ru) | 2011-04-18 | 2017-07-28 | Диамир, Ллс | Способы обнаружения патологических изменений в органе или системе органов |
| CN102188719B (zh) * | 2011-05-12 | 2012-12-19 | 南方医科大学 | EB病毒miR-BART3反义寡聚核苷酸在制备治疗鼻咽癌的药物中的应用 |
| RU2639509C2 (ru) | 2011-06-27 | 2017-12-21 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | МикроРНК - БИОМАРКЕРЫ, УКАЗЫВАЮЩИЕ НА БОЛЕЗНЬ АЛЬЦГЕЙМЕРА |
| CA2838562A1 (en) * | 2011-08-08 | 2013-02-14 | Eugenia Wang | Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof |
| CA3069089A1 (en) * | 2011-09-22 | 2013-03-28 | Lineage Biosciences, Inc. | Compositions and methods for analyzing heterogeneous samples |
| ITRM20110685A1 (it) | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
| US20160289762A1 (en) | 2012-01-27 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for profiliing and quantitating cell-free rna |
| HK1211624A1 (en) | 2012-01-27 | 2016-05-27 | The Board Of Trustees Of The University Of The Leland Stanford Junior University | Methods for profiling and quantitating cell-free rna |
| US20140087964A1 (en) * | 2012-09-24 | 2014-03-27 | University Of Virginia Patent Foundation | Compositions and methods for detecting aberrant regulation, expression, and levels of hgh |
| EP2733220B1 (en) * | 2012-11-16 | 2017-10-18 | Siemens Aktiengesellschaft | Novel miRNA as a diagnostic marker for Alzheimer's Disease |
| WO2014075822A1 (en) * | 2012-11-16 | 2014-05-22 | Siemens Aktiengesellschaft | New diagnostic mirna markers for parkinson disease |
| EP2733219B1 (en) | 2012-11-16 | 2017-09-20 | Siemens Aktiengesellschaft | Diagnostic miRNA markers for Alzheimer |
| CN103045736B (zh) * | 2012-12-20 | 2014-09-17 | 徐勇 | 唐氏综合征21号染色体miRNA差异表达图谱模型、构建方法及应用 |
| CN103045596A (zh) * | 2012-12-20 | 2013-04-17 | 徐勇 | 唐氏综合征21号染色体相关miRNA、基因、筛选方法和应用 |
| EP2759602A1 (en) * | 2013-01-25 | 2014-07-30 | Charité - Universitätsmedizin Berlin | Non-invasive prenatal genetic diagnostic methods |
| EP3611262B1 (en) | 2013-03-15 | 2020-11-11 | Lineage Biosciences, Inc. | Methods of sequencing the immune repertoire |
| CN105917005B (zh) | 2013-11-18 | 2020-09-11 | 迪阿米尔有限责任公司 | 使用来自体液的miRNA检测和监控帕金森病(PD)的方法 |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| TWI813141B (zh) | 2014-07-18 | 2023-08-21 | 香港中文大學 | Ｄｎａ混合物中之組織甲基化模式分析 |
| JP6873921B2 (ja) | 2015-05-18 | 2021-05-19 | カリウス・インコーポレイテッド | 核酸の集団を濃縮するための組成物および方法 |
| WO2017019751A1 (en) | 2015-07-27 | 2017-02-02 | The Johns Hopkins University | Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: pcr and sequencing based process methods |
| JP2018526021A (ja) * | 2015-09-11 | 2018-09-13 | コーニング インコーポレイテッド | 血液試料からの核酸精製のための組成物及び方法 |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| US11149313B2 (en) | 2016-03-21 | 2021-10-19 | Diamir, Llc | Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases |
| WO2018045359A1 (en) * | 2016-09-02 | 2018-03-08 | Karius, Inc. | Detection and treatment of infection during pregnancy |
| WO2018090054A1 (en) | 2016-11-14 | 2018-05-17 | Berg Llc | Methods for treating parkinson's disease |
| KR20260032575A (ko) | 2016-11-30 | 2026-03-09 | 더 차이니즈 유니버시티 오브 홍콩 | 소변 및 기타 샘플에서의 무세포 dna의 분석 |
| US10907211B1 (en) | 2017-02-16 | 2021-02-02 | Quantgene Inc. | Methods and compositions for detecting cancer biomarkers in bodily fluids |
| US10781487B2 (en) | 2017-07-24 | 2020-09-22 | Diamir, Llc | miRNA-based methods for detecting and monitoring aging |
| GB2615975B (en) | 2019-02-14 | 2023-11-29 | Mirvie Inc | Methods and systems for determining a pregnancy-related state of a subject |
| KR102802718B1 (ko) * | 2019-10-29 | 2025-04-30 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 뇌경색 치료 지원 시스템 |
| US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
| US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
| US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856088A (en) * | 1989-07-11 | 1999-01-05 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
| US5168039A (en) * | 1990-09-28 | 1992-12-01 | The Board Of Trustees Of The University Of Arkansas | Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis |
| US6020124A (en) * | 1992-04-27 | 2000-02-01 | Trustees Of Dartmouth College | Detection of soluble gene sequences in biological fluids |
| JP3435163B2 (ja) * | 1993-07-20 | 2003-08-11 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 黒色腫阻害蛋白質 |
| AU7375794A (en) | 1993-07-28 | 1995-02-28 | Akzo Nobel N.V. | Process for isolating nucleic acid from gram positive microorganisms |
| CA2170604C (en) * | 1993-08-30 | 2007-03-13 | Vikas V. Padhye | Nucleic acid purification compositions and methods |
| US5631130A (en) * | 1994-05-13 | 1997-05-20 | Abbott Laboratories | Materials and methods for the detection of Mycobacterium tuberculosis |
| AU703947B2 (en) * | 1994-06-09 | 1999-04-01 | Innogenetics N.V. | Method for the detection of the antibiotic resistance spectrum of mycobacterium species |
| US5731150A (en) * | 1995-11-01 | 1998-03-24 | Chiron Diagnostic Corporation | IS6110 based molecular detection of mycobacterium tuberculosis |
| US6027945A (en) * | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
| US6492144B1 (en) * | 1997-05-30 | 2002-12-10 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| US6251638B1 (en) * | 1997-05-30 | 2001-06-26 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| US20020119478A1 (en) * | 1997-05-30 | 2002-08-29 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| US5962665A (en) | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| US20060204989A1 (en) † | 1998-09-22 | 2006-09-14 | Kopreski Michael S | Comparative analysis of extracellular RNA species |
| US7196183B2 (en) * | 2001-08-31 | 2007-03-27 | Innogenetics N.V. | Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent |
| US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
| EP2290073A3 (en) * | 2004-05-28 | 2011-08-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| WO2006089203A2 (en) | 2005-02-17 | 2006-08-24 | Istituto Nazionale Per Le Malattie Infettive Irccs Lazzaro Spallanzani | Compositions and methods for detecting viral specific nucleic acids in urine |
| ITRM20050067A1 (it) * | 2005-02-17 | 2006-08-18 | Istituto Naz Per Le Malattie I | Metodo per la rivelazione di acidi nucleici virali o di origine virale nelle urine. |
| EP2351857B1 (en) | 2005-02-17 | 2014-10-29 | TrovaGene, Inc. | Compositions and methods for detecting pathogen specific nucleic acids in urine |
| ITRM20050068A1 (it) * | 2005-02-17 | 2006-08-18 | Istituto Naz Per Le Malattie I | Metodo per la rivelazione di acidi nucleici di agenti patogeni batterici o di parassiti nelle urine. |
| US7914982B2 (en) * | 2005-02-17 | 2011-03-29 | Trovagene, Inc. | Methods for detecting pathogen specific nucleic acids in urine |
| US20060292616A1 (en) * | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
| DE102005059315A1 (de) * | 2005-12-09 | 2007-06-14 | Qiagen Gmbh | Verfahren zur Anreicherung von kurzkettigen Nukleinsäuren |
| US20070202511A1 (en) * | 2006-02-28 | 2007-08-30 | Sigma-Aldrich Co. | Methods and compositions for the rapid isolation of small RNA molecules |
| EP2853601B1 (en) * | 2008-07-18 | 2016-09-21 | TrovaGene, Inc. | Methods for PCR-based detection of "ultra short" nucleic acid sequences |
-
2008
- 2008-08-22 HU HUE08795523A patent/HUE019019T5/en unknown
- 2008-08-22 HR HRP20130618AT patent/HRP20130618T1/hr unknown
- 2008-08-22 TR TR2018/02758T patent/TR201802758T4/tr unknown
- 2008-08-22 CA CA2696403A patent/CA2696403C/en not_active Expired - Fee Related
- 2008-08-22 AU AU2008289447A patent/AU2008289447B2/en not_active Ceased
- 2008-08-22 CN CN201510649676.8A patent/CN105400868B/zh not_active Expired - Fee Related
- 2008-08-22 PT PT131619850T patent/PT2612926T/pt unknown
- 2008-08-22 EP EP08795523.3A patent/EP2195450B2/en not_active Not-in-force
- 2008-08-22 PT PT87955233T patent/PT2195450E/pt unknown
- 2008-08-22 US US12/229,378 patent/US8486626B2/en not_active Expired - Fee Related
- 2008-08-22 WO PCT/US2008/009991 patent/WO2009025852A2/en not_active Ceased
- 2008-08-22 ES ES13161985.0T patent/ES2660785T3/es active Active
- 2008-08-22 PL PL13161985T patent/PL2612926T3/pl unknown
- 2008-08-22 JP JP2010521887A patent/JP5416110B2/ja not_active Expired - Fee Related
- 2008-08-22 PL PL08795523T patent/PL2195450T3/pl unknown
- 2008-08-22 EP EP13161985.0A patent/EP2612926B1/en not_active Not-in-force
- 2008-08-22 DK DK13161985.0T patent/DK2612926T3/en active
- 2008-08-22 NO NO13161985A patent/NO2612926T3/no unknown
- 2008-08-22 ES ES08795523.3T patent/ES2415245T5/es active Active
- 2008-08-22 CN CN200880113585.0A patent/CN101861399B/zh not_active Expired - Fee Related
- 2008-08-22 DK DK08795523.3T patent/DK2195450T4/en active
-
2013
- 2013-07-03 CY CY20131100546T patent/CY1114111T1/el unknown
- 2013-07-16 US US13/942,706 patent/US20150197805A1/en not_active Abandoned
-
2014
- 2014-08-11 AU AU2014210676A patent/AU2014210676B2/en not_active Ceased
-
2017
- 2017-01-06 US US15/400,157 patent/US20180135126A1/en not_active Abandoned
-
2018
- 2018-09-21 US US16/138,338 patent/US20200283851A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5416110B2 (ja) | ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法 | |
| JP2010536372A5 (https=) | ||
| CN106029900B (zh) | 尿生物标志物群、基因表达特征及其使用方法 | |
| CN112980941B (zh) | 一种诊断受试者是否患阿尔茨海默病的试剂盒及其用途 | |
| CN111733227A (zh) | 特发性视神经炎诊断分子标记物circRNA、试剂盒及应用 | |
| KR102545543B1 (ko) | BK 바이러스 신병증의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도 | |
| KR102505618B1 (ko) | 신장이식 후 항체 매개성 거부반응의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도 | |
| KR102505617B1 (ko) | 신장이식 후 T 세포 매개성 거부반응의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도 | |
| CN105950705A (zh) | 一组microRNAs在制备阿尔兹海默氏症诊断试剂或诊断试剂盒中的应用 | |
| HK1218767B (zh) | 使用mirna检测体内细胞死亡情况的方法 | |
| JP5988022B2 (ja) | ソラフェニブの効果予測方法 | |
| CN111363808B (zh) | 一种与阿尔茨海默相关的生物标志物及其应用 | |
| WO2024200806A1 (en) | Gene transcripts as signatures for tead-active cancer | |
| CN111826437A (zh) | 检测cyp46a1基因表达的产品在制备诊断非酒精性脂肪性肝病工具中的应用 |